Eli Lilly and Company (NYSE:LLY) Trading Down 1.2% – Should You Sell?

Eli Lilly and Company (NYSE:LLY)’s share price dropped 1.2% on Tuesday . The company traded as low as $1,229.79 and last traded at $1,231.9650. Approximately 2,124,000 shares were traded during trading, a decline of 31% from the average session volume of 3,090,796 shares. The stock had previously closed at $1,246.93.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Foundayo expands Lilly’s oral obesity-drug opportunity. The company launched its once-daily weight-loss and diabetes pill in the U.K., giving patients an oral alternative to injectable GLP-1 treatments and creating a potential new growth channel in Europe. Eli Lilly launches oral weight-loss pill Foundayo in UK
• Positive Sentiment: FDA clearance adds a diagnostics catalyst. The FDA cleared an Alzheimer’s blood test developed by Roche and Eli Lilly to help identify signs of disease in people aged 55 and older with cognitive decline. The test could broaden Lilly’s commercial exposure beyond diabetes and obesity therapies. Roche, Eli Lilly’s Alzheimer’s blood test gets FDA clearance
• Positive Sentiment: Investor and pipeline support remains strong. Citadel reportedly increased its Eli Lilly position nearly fourfold to roughly $1.1 billion, while early-stage studies of LY4395089 and LY3549492 continue to advance. These developments reinforce confidence in Lilly’s long-term pipeline, although neither experimental program is yet a near-term revenue driver. Eli Lilly Stock in Focus as Hedge Fund Titan Ken Griffin Quadruples Position
• Neutral Sentiment: Competitive comparisons are favorable but valuation is demanding. Analysts continue to point to Lilly’s stronger growth outlook versus some large pharmaceutical peers and Novo Nordisk. However, commentary also highlights that the shares already reflect significant future success, making further gains dependent on sustained execution and guidance upgrades. Eli Lilly Stock Raised Its Forecast, So Why Is the Market Shrugging?
• Negative Sentiment: Coverage concerns are weighing on demand expectations. Some employers and companies are declining to cover weight-loss medicines, viewing obesity treatments as optional rather than essential care. Any limits on reimbursement could slow patient adoption, pressure pricing, and temper expectations for Lilly’s GLP-1 revenue growth. Eli Lilly Stock Rattled as Companies Decline to Cover Weight-Loss Drug Costs

Analyst Upgrades and Downgrades

LLY has been the topic of several research reports. Weiss Ratings lowered Eli Lilly and Company from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday, August 11th. Sanford C. Bernstein increased their target price on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a research note on Tuesday, July 14th. Jefferies Financial Group raised their target price on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the company a “buy” rating in a report on Tuesday, June 9th. Morgan Stanley reissued an “overweight” rating and set a $1,419.00 price target on shares of Eli Lilly and Company in a research report on Thursday, August 6th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $1,400.00 price target on shares of Eli Lilly and Company in a report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $1,292.18.

Eli Lilly and Company Trading Down 1.2%

The business’s 50-day simple moving average is $1,182.50 and its two-hundred day simple moving average is $1,061.66. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. The company has a market capitalization of $1.16 trillion, a PE ratio of 41.34, a PEG ratio of 1.48 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The business had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. During the same period in the previous year, the company earned $6.31 earnings per share. The company’s revenue for the quarter was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, analysts predict that Eli Lilly and Company will post 36.35 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be given a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s dividend payout ratio is presently 23.22%.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 2,000 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the sale, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the transaction, the executive vice president owned 11,875 shares in the company, valued at $14,131,250. This trade represents a 29.63% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Eli Lilly and Company

A number of institutional investors have recently modified their holdings of LLY. Osbon Capital Management LLC bought a new stake in Eli Lilly and Company in the fourth quarter valued at about $25,000. Basso Capital Management L.P. bought a new position in Eli Lilly and Company during the 4th quarter worth approximately $30,000. E Fund Management Hong Kong Co. Ltd. grew its position in shares of Eli Lilly and Company by 342.9% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after acquiring an additional 24 shares in the last quarter. New England Capital Financial Advisors LLC increased its holdings in shares of Eli Lilly and Company by 142.9% in the 4th quarter. New England Capital Financial Advisors LLC now owns 34 shares of the company’s stock valued at $37,000 after acquiring an additional 20 shares during the last quarter. Finally, Maseco LLP raised its position in shares of Eli Lilly and Company by 466.7% during the 1st quarter. Maseco LLP now owns 34 shares of the company’s stock valued at $31,000 after acquiring an additional 28 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.